The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Zepzelca lurbinectedin OrphanAdditional monitoring | Pharma Mar S.A. | Small Cell Lung Carcinoma | 🇪🇺 EU 2026-05-29 | Order → |
| Adstiladrin nadofaragene firadenovec ATMPConditionalAdditional monitoring | Ferring Pharmaceuticals A/S | Non-Muscle Invasive Bladder Neoplasms | 🇪🇺 EU 2026-05-28 | Order → |
| Decnupaz pivekimab sunirine-pvzy New biologicPriority review | Abbvie Inc | 🇺🇸 US 2026-05-27 | Order → | |
| Differin Epiduo Acne Gel (Adapalene And Benzoyl Peroxide) adapalene, adapalene, benzoyl peroxide, benzoyl peroxide Rx-to-OTC switch | Galderma Labs Lp | 🇺🇸 US 2026-05-22 | Order → | |
| Hepcludex bulevirtide-gmod New biologicPriority review | Gilead Sciences Inc | 🇺🇸 US 2026-05-22 | Order → | |
| Joenja leniolisib OrphanExceptional circumstancesAdditional monitoring | Pharming Technologies B.V. | Primary Immunodeficiency Diseases | 🇪🇺 EU 2026-05-21 | Order → |
| Baxfendy baxdrostat New molecular entityPriority review | Astrazeneca Ab | 🇺🇸 US 2026-05-15 | Order → | |
| Immgolis golimumab-sldi Biosimilar | Accord Biopharma Inc. | 🇺🇸 US 2026-05-15 | Order → | |
| Trimbow beclomethasone dipropionate, formoterol fumarate, glycopyrrolate New combination | Chiesi | 🇺🇸 US 2026-05-14 | Order → | |
| Beqalzi sonrotoclax New molecular entityPriority review | Beone Medicines Usa | 🇺🇸 US 2026-05-13 | Order → | |
| Ennumo pegfilgrastim-pccg Biosimilar | Accord Biopharma Inc. | 🇺🇸 US 2026-05-07 | Order → | |
| Bysumlog insulin lispro BiosimilarAdditional monitoring | Sandoz GmbH | Diabetes Mellitus | 🇪🇺 EU 2026-05-06 | Order → |
| Evdi trabectedin New formulation or manufacturer | Apotex | 🇺🇸 US 2026-05-01 | Order → | |
| Jakafi Xr ruxolitinib phosphate New formulation or manufacturer | Incyte Corp | 🇺🇸 US 2026-05-01 | Order → | |
| Veppanu vepdegestrant New molecular entity | Rigel Pharms | 🇺🇸 US 2026-05-01 | Order → | |
| Langlara insulin glargine-aldy Biosimilar | Sunshine Lake Pharma Co Ltd | 🇺🇸 US 2026-04-29 | Order → | |
| Dazparda insulin aspart BiosimilarAdditional monitoring | Sandoz GmbH | Diabetes Mellitus | 🇪🇺 EU 2026-04-27 | Order → |
| Onerji levodopa;carbidopa | Tanabe Pharma GmbH | Parkinson Disease | 🇪🇺 EU 2026-04-27 | Order → |
| Tuyory tocilizumab BiosimilarAdditional monitoring | Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.) | Arthritis, Rheumatoid; Arthritis, Juvenile; Cytokine Release Syndrome; Giant Cell Arteritis; COVID-19 virus infection | 🇪🇺 EU 2026-04-27 | Order → |
| Xolremdi mavorixafor OrphanExceptional circumstancesAdditional monitoring | Norgine B.V. | Primary Immunodeficiency Diseases | 🇪🇺 EU 2026-04-27 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.